Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells

BACKGROUND: The bone-targeting agent zoledronic acid (ZOL) increases breast cancer survival in subsets of patients, but the underlying reasons for this protective effect are unknown. ZOL modulates the activity of osteoclasts and osteoblasts, which form hematopoietic stem cell niches, and therefore m...

Descripción completa

Detalles Bibliográficos
Autores principales: Ubellacker, Jessalyn M., Haider, Marie-Therese, DeCristo, Molly J., Allocca, Gloria, Brown, Nicola J., Silver, Daniel P., Holen, Ingunn, McAllister, Sandra S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339994/
https://www.ncbi.nlm.nih.gov/pubmed/28264701
http://dx.doi.org/10.1186/s13058-017-0815-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339994/
https://www.ncbi.nlm.nih.gov/pubmed/28264701
http://dx.doi.org/10.1186/s13058-017-0815-8

Ejemplares similares